boston scientific presents industry more durable battery for the dai and crt d leading the market

Paris, may 2012.- Boston Scientific Corporation (NYSE: BS) has announced that you extend up to 10 years, depending on the model, the guarantee of the implantable defibrillators (DAI) Energen ™ and defibrillators (CRT-D) cardiac resynchronization therapy Incepta ™. This new program offers the longest guarantees in the industry and provides doctors, patients and responsible for funding until 5 years of guarantee than other heart devices available today. In particular:

DAI VR Energen and Incepta ·: 10 years warranty on the device;

DAI DR Energen and Incepta ·: 8 years of warranty on the device;

CRT-D Energen and Incepta ·: 6 years of warranty of the device.

“having this type of guarantee on devices provides doctors a longer duration of battery safety and offers greater peace of mind to patients.” «This is a factor of great importance when selecting a device particularly for the implant “, said Dr. Oliver Przibille, a distinguished fellow of the European Society of Cardiology of the CCB, Herzschrittmacher-Centrum in Frankfurt, Germany.

«»the warranty extension program is a robust basis for the DAI and CRT-D’s latest generation of Boston Scientific, as well as a plan of development for future devices. «At the same time, confirms our continuous commitment to collaboration with doctors and patients, and our role as innovative company in the field of control of heart rate», declared Micael Onuscheck, Vice President and President of Boston Scientific in Europe, Middle East and Africa.

Along with medications, lifestyle changes and other surgical options, the DAI and the CRT-D are used to improve cardiac function and rhythm. These devices offer benefits capable of saving the lives of patients through the prevention of sudden cardiac death and play an important role in the treatment of heart failure, a progressive disease for which there is no cure and in which the heart is unable to pump blood effectively. The DAI and the Boston Scientific (CRT-d) have greater duration batteries of the industry, which could lead to a smaller number of implants throughout the life of the patient, resulting in a reduction of complications and savings for health systems.

«From the psychological point of view, the guarantee of greater duration of the battery has a very positive effect in the perception and acceptance of the patient for this type of treatment, because a prolonged guarantee means that the devices have been manufactured to last»said Dr. Roberto Verlato, head of the cardiology department of the Camposampiero Hospital, Italy.

Boston Scientific assurance program is based on data obtained in real circumstances with 67,000 dispostivos1 fitted with a new battery of advanced technology of the company, which offers a greater capacity than other DAI and CRT-D, as well as having numerous features designed to save energy.

Today, 14 million Europeans suffer from heart failure, a figure that could increase to 30 million by 2020, as a result of the ageing of the population and the effectiveness of the latest treatments to prolong survival of patients. Heart failure is linked to a high frequency of hospital admissions, which constitutes the main component of the cost of your treatment (67-75%). On average, the cost of treating heart failure is equivalent to 1-2% of the total health budget of each European country.

For more information on the Boston Scientific guarantees program visit: http://www.epresspack.net/bsci.

About Boston Scientific

Boston Scientific is a company dedicated to the development, manufacturing and international marketing of medical devices, which are used in a wide range of medical specialties interventionist.

1. 2 August 2011 data obtained from the patients bearers of Boston Scientific devices supervised by the LATITUDE system ™.